Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EF2001
- Development stage
- Unknown
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EF2001 is a **heat-killed preparation of the probiotic bacterium Enterococcus faecalis**, used primarily as a dietary supplement and investigated for metabolic and gut health benefits. Mechanistically, EF2001 modulates lipid metabolism, decreasing lipid accumulation and hepatic steatosis in animal models by activating the **AMP-activated protein kinase (AMPK) pathway** and promoting phosphorylation of acetyl-CoA carboxylase (ACC), while suppressing lipogenic transcription factors such as SREBP-1c and enzymes like fatty acid synthase (FAS) and HMG-CoA reductase. EF2001 also possesses **anti-inflammatory effects** in the gut, reducing the expression of pro-inflammatory cytokines (such as iNOS, COX-2, IFN-γ, IL-1β, IL-6) and mitigating symptoms in mouse models of inflammatory bowel disease. Trials are ongoing to assess its benefits in obese and overweight individuals for gut health and metabolic dysfunction[1][2][3][5].
- Brand names
- EF2001EF-2001EF 2001
- Other names
- Enterococcus faecalis EF-2001heat-killed Enterococcus faecalis EF-2001
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)IL-6 (Interleukin 6)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ACC (Acetyl-CoA Carboxylase 1)PPARG (Peroxisome proliferator-activated receptor gamma)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)RELA (Nuclear Factor Kappa B Subunit p65)TLR2 (Toll-like Receptor 2)TNFA (Tumor necrosis factor alpha (soluble))SREBP-1 / SREBF1 (SREBP-1)XIAPIL1B (Interleukin-1 beta)FASN (Fatty acid synthase)
Beyond the preview
Go deeper on EF2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EF2001.